Probiotics for Prevention of Atopy and Food Hypersensitivity in Early Childhood

A PRISMA-Compliant Systematic Review and Meta-Analysis of Randomized Controlled Trials

Guo-Qiang Zhang, MSc, Hua-Jian Hu, MD, Chuan-Yang Liu, MSc, Qiao Zhang, MSc, Shristi Shukla, MD, and Zhong-Yue Li, MD

Abstract: Most studies investigated probiotics on food hypersensitivity, not on oral food challenge confirmed food allergy in children. The authors systematically reviewed the literature to investigate whether probiotic supplementation prenatally and/or postnatally could reduce the risk of atopy and food hypersensitivity in young children.

PubMed, Embase, the Cochrane Central Register of Controlled Trials, and 4 main Chinese literature databases (Wan Fang, VIP, China National Knowledge Infrastructure, and Sinomed) were searched for randomized controlled trials regarding the effect of probiotics on the prevention of allergy in children. The last search was conducted on July 11, 2015.

Seventeen trials involving 2947 infants were included. The first follow-up studies were analyzed. Pooled analysis indicated that probiotics administered prenatally and postnatally could reduce the risk of atopy (relative risk [RR] 0.78; 95% confidence interval [CI] 0.66–0.92; I² = 0%), especially when administered prenatally to pregnant mother and postnatally to child (RR 0.71; 95% CI 0.57–0.89; I² = 0%), and the risk of food hypersensitivity (RR 0.77; 95% CI 0.61–0.98; I² = 0%). When probiotics were administered either only prenatally or only postnatally, no effects of probiotics on atopy and food hypersensitivity were observed.

INTRODUCTION

Over the last few decades, there has been a sharp rise in the global prevalence of allergic diseases, such as asthma, eczema, and allergic rhinitis. At present, it is estimated that 1 in 5 persons worldwide would be affected by some form of allergic diseases. Atopic disorders can have significant effects on morbidity and quality of life and can be costly in terms of medical visits and treatments, which therefore prompts considerable interest in generating efficient approaches for the prevention of allergic disorders.

The hygiene hypothesis proposed by Strachan in 1989, suggested that increased cleanliness, reduced family size, and decreased childhood infections could explain the increasing prevalence of allergic diseases. In the light of such a conception, a gut flora hypothesis has been formulated, suggesting that alterations in the gut microbiota, the most massive source of microbial exposure and a critical source of early immune stimulation, may underlie the atopic epidemic. In this perspective, supplementing microbes using probiotics, defined as “live microorganisms which, when administered in adequate amounts, confer a health benefit to the host” by the World Health Organization, seems an attractive way to prevent allergic disorders. Several experimental and observational studies have emphasized in the maintenance of normal gut microbes and development of atopic disorders. Biological mechanisms with respect to the protective role of probiotics in atopy remain unclear, but are plausible through reduced exposure to allergens by improved epithelial barrier function and immunoregulation to prevent immunoglobulin (Ig) E sensitization.

Several studies were designed to examine the efficacy of probiotics in the prevention of allergic disorders in the last decade. Studies on atopic sensitization and food hypersensitivity, however, conveyed conflicting results. Moreover, because
of small sample sizes, these reports were underpowered to detect the effect of probiotics on atopy or food hypersensitivity. Thus, to provide the latest and most convincing evidence, we performed a meta-analysis of randomized controlled trials (RCTs) to assess whether probiotic supplementation during pregnancy and/or infancy could reduce the risk of atopy or food hypersensitivity in young children.

METHODS

This systematic review and meta-analysis was conducted and reported in adherence to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement and the guidelines of the Cochrane Handbook for Systematic Reviews of Interventions. Because our study was a review of previous published studies, ethical approval or patient consent was not required.

Literature Search and Selection Criteria

In July 2015, we performed a systematic literature search in PubMed, Embase, and the Cochrane Central Register of Controlled Trials for RCTs evaluating the effects of probiotic supplementation on allergic diseases in children. We also searched ClinicalTrials.gov, European Union Clinical Trials Register, and 4 main Chinese literature databases, that is, Wan Fang, VIP, China National Knowledge Infrastructure, and SinoMed. The last search was conducted on July 11, 2015. In all databases, we used the following keywords: “probiotic”, “probiotics”, “food allergy”, “food hypersensitivity”, “atopy”, “allergy”, “immunoglobulin”, “IgE”, “sensitization”, or “eczema”. The search was restricted to clinical trials conducted in humans. No language restriction was imposed. The search strategy is shown in Table 1. We also manually checked the references of the retrieved articles and previous reviews to identify additional eligible studies. Two review team members (G-QZ and H-JH) independently conducted the initial search, deleted duplicate records, screened the titles and abstracts for relevance, checked the reference lists of all records of interest for other pertinent publication, and identified as excluded or requiring further assessment. Then, we reviewed the full-text articles for inclusion. Abstracts and unpublished studies were not included.

We developed a PICOS (Patient, Intervention, Comparators, Outcome, and Study design) approach as the eligibility criteria: 1) Population: children in whom outcome assessment performed during infancy or childhood (ie, up to 12 years of age), without atopic diseases at the time of probiotic administration; 2) Intervention: any species/strains/doses regimen of live probiotics administered prenatally and/or postnatally within age), without atopic diseases at the time of probiotic administration; 3) Comparator: placebo or no probiotics; 4) Outcome: the primary outcome was atopic sensitization, and the secondary outcome was food sensitization. Sensitization was defined as a positive result on a skin prick test (SPT) and/or elevated specific IgE (>0.35 kU/L) to any allergen, food allergens, or aeroallergens; 5) Study design: only RCTs. We excluded interventions other than live probiotics, administration of probiotics with prebiotics, and those focused on treatment of atopic diseases. When studies used the same population, the earliest publication was included in the meta-analysis, because of lower dropout rates and an end point more similar to other studies. Discrepancies regarding study inclusion between review team members were resolved through discussion with a third reviewer (Z-YL), as required.

Data Extraction and Quality Assessment

Data extraction was performed by H-JH and confirmed independently by G-QZ. The following information were extracted from each study: source (first author), intervention period (prenatal and/or postnatal), number of participants in the intervention and control groups, strains/doses/duration of probiotics administered, control group, outcomes (atopic sensitization or food sensitization), definition of sensitization, and end of follow-up. When data were separately reported on positive SPT and elevated IgE, data on positive SPT were selected. Extracted data were entered into a standardized Word file. Disagreement was further checked on the original articles, and was resolved. The Cochrane Risk of Bias Tool was adopted to assess the risk of bias for each RCT.

Statistical Analysis

To evaluate the effects of probiotics, we calculated relative risks (RRs) for the development of sensitization between intervention and control groups. When trials investigated 2 separate probiotic groups versus placebo, data on the 2 probiotic groups were combined into a single RR, which we included in the meta-analysis. Heterogeneity across studies was tested by using the $I^2$ statistic. Studies with an $I^2$ value greater than 50% were considered to have significant heterogeneity. The Mantel–Haenszel method with random effects model was used to calculate pooled RRs and 95% confidence intervals (CIs). Subgroup analyses were conducted according to intervention subject, duration of intervention, probiotic dose, probiotic organism, end of follow-up, risk of allergic diseases, caesarean delivery rate, geographical area, and risk of bias. An assessment of publication bias was performed by visually inspecting funnel plot and by using the Begg’s and Egger’s tests. A $P$ value less than 0.05 was considered as statistically significant, except where otherwise specified. All the statistical analyses were performed using the Stata 12.0 (Stata Corporation, College Station, TX) and RevMan 5.3 (The Nordic Cochrane Centre, Copenhagen, Denmark).

RESULTS

Figure 1 shows a flow diagram for selection of articles. A total of 1352 articles were identified by the initial databases search. Total 235 articles were excluded for duplicates. By examining the titles and abstracts, an additional 1091 articles were excluded as irrelevant (reviews, letters, animal studies, or treatment of atopic diseases). The remaining 26 full-text articles were retained for further consideration, and 9 studies were excluded because they were extended follow-up publications. Finally, the remaining 17 trials were included in the meta-analysis.
Characteristics of Included Studies

The main characteristics of included studies are described in Table 2. Studies that were included were published between 2001 and 2014. All trials were randomized, double-blinded, and placebo-controlled. Ten trials were conducted in Europe, 28,30–33,36,37,39,42,43 4 in Asia,35,38,41,44 2 in Australia,34,40 and 1 in New Zealand.29 Based on family history, 12 trials enrolled participants at high risk for allergy,29–32,34–41 and the remaining 5 were conducted in unselected populations. Probiotics were administered prenatally in 1 trial,34 prenatally to pregnant mothers and postnatally to mothers or directly to children in 12 trials,28–32,35–37,39,42,44 and only postnatally to infants in 4 trials.33,38,40,43 Seven trials used Lactobacillus,30,34,36,39,41,43 1 trial used Bifidobacterium,44 and 8 trials used probiotic mixtures.28,31–33,38,42 Wickens et al29 used separate Lactobacillus and Bifidobacterium arms compared with 1 placebo group. All the included studies reported data on probiotics for the prevention of atopic sensitization, and 9 studies for food sensitization.28,29,31,32,34,36,37,39,40

Atopic Sensitization

Seventeen trials including 2947 children contributed atopic sensitization data for meta-analysis, shown in Figure 2. Overall, there was no significant effect of probiotic supplementation on the risk of atopic sensitization (RR 0.89, 95% CI 0.77–1.03, $I^2 = 9\%$). Significantly beneficial effects were observed when probiotics were administered both prenatally and postnatally (RR 0.78, 95% CI 0.66–0.92, $I^2 = 0\%$), but not when administered only prenatally to pregnant mother (RR 1.00, 95% CI 0.68–1.48) or only postnatally to infant (RR 1.36, 95% CI 1.00–1.86, $I^2 = 0\%$). There was no evidence of significant publication bias by inspection of the funnel plot and formal statistical tests (Egger’s test, $P = 0.988$; Begg’s test, $P = 0.773$; Figure 3).

Subgroup Analysis

Table 4 reports the pooled RRs for probiotic supplementation prenatally and postnatally in the prevention of atopic

---

**FIGURE 1.** Selection process for the studies included in the meta-analysis.
| Source          | Intervention Period | Experimental/Control | Strains, Doses, and Duration | Control Group | Outcomes          | Definition of Sensitization | End of Follow-up |
|-----------------|---------------------|----------------------|------------------------------|---------------|-------------------|------------------------------|------------------|
| Allen<sup>28</sup> | Prenatal and postnatal | 220/234 (mixed) | A mixture of *L. salivarius*, *L. panacaei*, *B. animalis*, and *B. bifidum*, 1 × 10<sup>10</sup> CFU/d, from 36 wk gestation to delivery (mother), then from birth to age 6 mo (child) | Placebo Group | Atopy            | Positive SPT           | 2 y of age       |
| Wickens<sup>29</sup> | Prenatal and postnatal | 170/171/171 (high risk) | *L. rhamnosus* 6 × 10<sup>7</sup> CFU/d, or *B. animalis* 9 × 10<sup>6</sup> CFU/d, from 35 wk gestation to 6 mo if breastfeeding (mother), then from birth to 2 y (child) | Placebo Group | Atopy and food sensitization | Positive SPT            | 2 y of age       |
| Kalliomaki<sup>30</sup> | Prenatal and postnatal | 77/82 (high risk) | *L. rhamnosus* GG, 2 × 10<sup>9</sup> CFU/d, from 2 to 4 wk before expected delivery (mother) to 6 mo of children through breastfeeding or directly to child | Placebo Group | Atopy            | Positive SPT           | 2 y of age       |
| Rautava<sup>31</sup> | Prenatal and postnatal | 81/82/78 (high risk) | A mixture of *L. rhamnosus* and *B. longum* or a mixture of *L. panacaei* and *B. longum*, 2 × 10<sup>9</sup> CFU/d, starting 2 mo before delivery and during the first 2 mo of breastfeeding (mother) | Placebo Group | Atopy            | Positive SPT           | 2 y of age       |
| Huurre<sup>32</sup> | Prenatal and postnatal | 72/68 (high risk) | A mixture of *L. rhamnosus* GG and *B. lactis*, 2 × 10<sup>9</sup> CFU/d, from the first trimester of pregnancy to the end of exclusive breastfeeding (mother) | Placebo Group | Atopy            | Positive SPT           | 1 y of age       |
| Boyle<sup>34</sup> | Prenatal | 125/125 (high risk) | *L. rhamnosus* GG, 1.8 × 10<sup>8</sup> CFU/d, from 36 wk gestation to delivery | Placebo Group | Atopy            | Positive SPT           | 1 y of age       |
| Kim<sup>35</sup> | Prenatal and postnatal | 57/55 (high risk) | A mixture of *B. bifidum*, *B. lactis*, and *L. acidophilus*, 4.8 × 10<sup>9</sup> CFU/d, from 8 wk before delivery to 3 mo after delivery (mother), then from 4 to 6 mo of age (child) | Placebo Group | Atopy and food sensitization | Circulating IgE > 0.35 kU/L | 1 y of age       |
| Kopp<sup>36</sup> | Prenatal and postnatal | 54/51 (high risk) | *L. rhamnosus* GG, 1 × 10<sup>9</sup> CFU/d, from 4 to 6 wk before delivery to 3 mo after delivery (mother), then from 4 to 6 mo of age (child) | Placebo Group | Atopy            | Inhalant allergen-specific IgE | 2 y of age       |
| Niers<sup>37</sup> | Prenatal and postnatal | 78/78 (high risk) | A mixture of *B. bifidum*, *B. lactis*, and *Lactococcus lactis*, 3 × 10<sup>9</sup> CFU/d, from 6 wk before term to delivery (mother), then from birth to 12 mo of age (child) | Placebo Group | Atopy and food sensitization | Positive SPT | 2 y of age       |
| Sohn<sup>38</sup> | Postnatal | 127/126 (high risk) | A mixture of *B. longum* and *L. rhamnosus*, at least 2.8 × 10<sup>9</sup> CFU/d, from birth to 6 mo of life (child) | Placebo Group | Atopy and food sensitization | Positive SPT | 1 y of age       |
| Abrahamsson<sup>39</sup> | Prenatal and postnatal | 117/115 (high risk) | *L. reuteri*, 1 × 10<sup>9</sup> CFU/d, from 4 wk before term to delivery (mother), then from birth to 12 mo of age (child) | Placebo Group | Atopy and food sensitization | Positive SPT | 1 y of age       |
| Taylor<sup>40</sup> | Postnatal | 115/111 (high risk) | *L. acidophilus*, 3 × 10<sup>9</sup> CFU/d, from birth to 6 mo of age (child) | Placebo Group | Atopy            | Positive SPT, circulating IgE > 0.35 kU/L | 1 y of age       |
| Ou<sup>41</sup> | Prenatal and postnatal | 95/96 (high risk) | *L. rhamnosus* GG, 1 × 10<sup>9</sup> CFU/d, from second trimester of pregnancy (mother) to 6 mo of children, through breastfeeding or directly to child | Placebo Group | Atopy            | Positive SPT, circulating IgE > 0.7 kU/L | 3 y of age       |
| Dotterud<sup>42</sup> | Prenatal and postnatal | 211/204 (mixed) | A mixture of *L. rhamnosus* GG, *L. acidophilus*, and *B. animalis*, 1.05 × 10<sup>11</sup> CFU/d, from 36 wk of gestation to 3 mo postnatally during breastfeeding (mother) | Placebo Group | Atopy            | Positive SPT | 2 y of age       |
| West<sup>43</sup> | Postnatal | 89/90 (mixed) | *L. paracasei*, 1 × 10<sup>9</sup> CFU/d, from 4 to 13 mo (child) | Placebo Group | Atopy            | Circulating IgE > 0.35 kU/L | 13 mo of age      |
| Wu<sup>44</sup> | Prenatal and postnatal | 36/36 (mixed) | *B. bifidum*, 1.5 × 10<sup>9</sup> CFU/d, from 36 wk of gestation to the end of exclusive breastfeeding (mother) | Placebo Group | Atopy and food sensitization | Circulating IgE | 2 y of age       |

**CFU** = colony-forming unit, **IgE** = immunoglobulin E, **SPT** = skin prick test.

<sup>L</sup> = *Lactobacillus*, <sup>B</sup> = *Bifidobacterium*. 
TABLE 3. Risk-of-Bias Assessment of the Included Randomized Controlled Trials

| Study          | Adequate Sequence Generation? | Allocation Concealment? | Blinding of Participants and Personnel | Blinding of Outcome Assessment | Incomplete Outcome Data? | Selective Reporting? | Other Bias? | Overall Risk of Bias |
|----------------|-------------------------------|-------------------------|----------------------------------------|-------------------------------|--------------------------|-----------------------|-------------|--------------------|
| Allen28        | Yes                           | Yes                     | Yes                                    | Yes                           | Unclear                  | No                    | No          | Unclear            |
| Wickens29      | Yes                           | Yes                     | Yes                                    | Yes                           | No                       | No                    | No          | Low                |
| Kalliomaki30    | Yes                           | Yes                     | Yes                                    | Yes                           | Unclear                  | No                    | No          | Unclear            |
| Rautava31      | Yes                           | Yes                     | Yes                                    | Yes                           | No                       | No                    | No          | Low                |
| Huurre32       | Yes                           | Unclear                 | Unclear                                | Yes                           | No                       | No                    | No          | Low                |
| Rautava33      | Yes                           | Unclear                 | Unclear                                | Yes                           | No                       | No                    | No          | Low                |
| Boyle34        | Yes                           | Yes                     | Yes                                    | Yes                           | Unclear                  | No                    | No          | Unclear            |
| Kim35          | Yes                           | Unclear                 | Yes                                    | Yes                           | No                       | No                    | No          | Unclear            |
| Kopp36         | Yes                           | Yes                     | Yes                                    | Yes                           | No                       | No                    | No          | Low                |
| Niers37        | Unclear                       | Yes                     | Yes                                    | Yes                           | No                       | No                    | No          | High               |
| Soh38          | Yes                           | Unclear                 | Yes                                    | Yes                           | No                       | No                    | No          | Unclear            |
| Taylor40       | Yes                           | Yes                     | Yes                                    | Yes                           | No                       | No                    | No          | High               |
| Ou41           | Unclear                       | Yes                     | Yes                                    | Yes                           | Yes                      | Unclear               | No          | High               |
| Dotterud42     | Yes                           | Yes                     | Yes                                    | Yes                           | Yes                      | No                    | No          | Low                |
| West43         | Yes                           | Unclear                 | Yes                                    | Yes                           | No                       | No                    | No          | Low                |
| Wu44           | Yes                           | Unclear                 | Yes                                    | Yes                           | No                       | No                    | No          | Low                |

Risk of bias was assessed with use of the Cochrane risk-of-bias tool.

FIGURE 2. Effect of probiotic supplementation on atopic sensitization.
Food Sensitization

Nine trials including 1506 children contributed food sensitization data for meta-analysis, shown in Figure 4. Overall, there was no significant effect of probiotics on the risk of food sensitization (RR 0.92, 95% CI 0.75–1.12, $I^2 = 7\%$). Significantly beneficial effects were observed when probiotics were administered both prenatally and postnatally (RR 0.77, 95% CI 0.61–0.98, $I^2 = 0\%$), but not when administered only prenatally to pregnant mother (RR 1.01, 95% CI 0.66–1.55) or only postnatally to infant (RR 1.43, 95% CI 0.94–2.18, $I^2 = 0\%$). There was no evidence of significant publication bias by inspection of the funnel plot and formal statistical tests (Egger’s test, $P = 0.806$; Begg’s test, $P = 0.917$; Figure 5).

**DISCUSSION**

The results of our meta-analysis indicate that probiotics administered prenatally and postnatally is effective in reducing the risk of atopy, particularly in families at high risk for allergy, and the risk of food hypersensitivity in young children. According to subgroup analyses, probiotics administered to both mother and child, or longer duration of intervention may be more effective in preventing atopy. In addition, cesarean-delivered children might particularly benefit from probiotic administration.

Several mechanisms might explain such an effect. First, colonizing the mother prenatally by supplementing probiotics, favorable bacteria could be transferred to the infant during birth. In addition, immunomodulation of the mother and changes in her breast milk composition could benefit the infant with respect to allergy development. Second, the gut is the most massive source of postnatal microbial exposure and a critical source of early immune stimulation, and probiotic supplementation early in life may modulate the maturation of the immune response. Differences in the gut microbiota composition have been observed before the development of allergic symptoms in several studies. The underlying mechanisms whereby probiotics prevent atopy might include producing a shift of the lymphocyte T helper 1 (Th1)/lymphocyte T helper 2 (Th2) balance toward a Th1 response and a consequent decreased secretion of Th2 cytokines, such as interleukin (IL)-4, IL-5, and IL-13, as well as decreased IgE, and increased production of C-reactive protein and IgA.

In our study, no effects of postnatal probiotic supplementation (direct to child), however, were observed, which implied that prenatal supplementation may be a more important factor in conferring these benefits. Only 1 study used solely prenatal supplementation, and no significant effect was observed between groups. Therefore, whether antenatal supplementation alone could account for such significant differences, or still needs to be further followed by stimulation of the infant’s gut immune system (probiotics administered preferably directly to...
the child), remains to be explored. Of note, the potential mechanisms behind the allergy-preventive effects afforded by probiotics remain a highly live issue, and what exactly constitutes a “healthy gut microbiome” that promotes tolerance is far from understood. Although the new World Allergy Organization guidelines suggested that probiotics should be recommended in mothers of high-risk infants and in infants at high risk of allergic disease, the recommendations are conditional and based on very low quality evidence, with no specific recommendation regarding strains, dose, treatment duration, etc. Hence, more work still needs to be done in this field.

We found that higher cesarean delivery rate group, compared with lower cesarean delivery rate, was associated with a lower risk of atopy when administered probiotics. Our result was consistent with the study by Kuitunen et al, which concluded that probiotic and prebiotic supplementation during pregnancy and infancy conferred protection preferably to cesarean-delivered children. It has been suggested that children born by means of cesarean section were colonized with beneficial microflora later than vaginally delivered children, and have higher risk of developing allergic disorders. We could speculate that cesarean-delivered children, who are deprived of massive microbial load from vaginal delivery, might particularly benefit from probiotic administration.

One of our aims was to summarize the data on probiotic use and food hypersensitivity. Guidelines published in 2014 by the European Academy of Allergy and Clinical Immunology’s Taskforce on the prevention of food allergy suggested that there was still no evidence to support the use of probiotics for food allergy prevention, which was primarily based on studies of probiotics and food hypersensitivity. Our pooled result indicated that probiotics administered prenatally and postnatally could reduce the risk of food hypersensitivity, with all included studies reporting results in the same direction. Our result was also consistent with previous reviews. Therefore, we speculate that probiotic supplementation prenatally and postnatally maybe a feasible way to prevent IgE-related food allergy in early life. Of note, our result was based on data from positive SPT and/or elevated specific IgE to food allergens rather than confirmed food allergy. And, food hypersensitivity is not always associated with clinical reactions and food allergy, although infants with food sensitization may be more prone to development of food hypersensitivity.
to develop food allergy. To our knowledge, studies exploring the effects of probiotics on confirmed food allergy are surprisingly scant. Two trials considered food allergy as outcome, either confirmed by allergic symptoms or reported by parents, reported totally opposite effects of probiotics but not statistically significant. Another 2 trials considered cow’s milk allergy as outcome, confirmed by cow’s milk challenge, and consistently suggested a preventative effect of probiotics but not statistically significant. Thus, although our study strongly suggested that probiotics administered prenatally and postnatally were effective in reducing the risk of food hypersensitivity, studies investigating the effects of probiotics on oral food challenge confirmed food allergy are still warranted.

During the last few decades, the nexus between allergic disorders and autoimmune diseases (such as multiple sclerosis, rheumatoid arthritis, and type 1 diabetes mellitus, etc.) has prompted considerable interest. One generally accepted concept, postulated by Sornasse et al in 1996, was that autoimmune and allergic disease was Th1- and Th2 mediated, respectively, which occurred in mutually exclusive populations of patients. Until recently, several observations have challenged this paradigm that the presence of allergic and autoimmune diseases are mutually exclusive states, and provided additional insight into the roles of mast cells, B cells, and some other subsets of T cells (such as, Th17 and regulatory T cells) as a common link between atopy and autoimmunity. There is growing body of evidence indicating that probiotics could modulate the immune response, such as the balance of Th1/Th2 cells, and prevent autoimmune and allergic diseases. Still, the exact mechanisms up to now are far from understood, and further clinical and experimental studies are needed to fully clarify such an effect.

Comparison With Previous Studies

Differences between the current meta-analysis and previous meta-analyses should be noted. A meta-analysis by Elazab et al evaluated the effect of probiotic supplementation during pregnancy or infancy on the prevention of atopy in young children. The authors included 15 RCTs involving 2797 children and concluded that probiotics administered prenatally and postnatally was associated with reduced risk of atopy (RR 0.88, 95% CI 0.78–0.99). Notably, the control groups of 2 included trials were double counted. Moreover, studies with the longest follow-up time were included, which resulted in big variation across included studies, that is, 12 studies with follow-up of 1 to 2 years and the other 3 studies with follow-up of 4 to 7 years. In another 2 meta-analyses focusing on food hypersensitivity, Osborn et al included 2 RCTs involving 247 children and found a lack of effect of probiotics on food hypersensitivity, and the recent meta-analysis conducted by Kong et al included 10 RCTs and yielded a similar nonsignificant result. Of note, 2 included RCTs were based on the same population, and 3 RCTs should be excluded because of ineligible intervention (probiotics administered with prebiotics) and ineligible participants (children with highly suspected cow’s milk allergy). Overall, the 3 previous meta-analyses had obvious flaws that might threaten the authenticity of their findings. After the 3 meta-analyses, several studies investigating probiotics for the prevention of atopy or food hypersensitivity were published. Our updated meta-analysis included 17 studies with a total of 2947 children and data were from studies with similar follow-up time. In contrast with the previous meta-analyses, the current 1 suggested that combined prenatal and postnatal supplementation of probiotics may reduce the risk of atopy and food hypersensitivity. Moreover, low heterogeneity, the consistency of findings in most subgroups, and lack of publication bias or other major biases added robustness to our main findings.

Several potential limitations should be taken into consideration when interpreting the results. First, although no statistical heterogeneity was found for the outcomes of interest, population characteristics, probiotic regimens (various organisms, daily doses, and length of intervention), and follow-up time differed across the included studies. We adopted random effects models to try to account for such variability. Second, to further examine the influence of these clinical factors on the pooled results and verify the robustness of our findings, subgroup analyses were conducted and the results were consistent in most selected subgroups. We, however, can only analyze factors that are available to us from the original articles. Also, subgroup analyses were susceptible to type II errors because of relatively small sample sizes. Third, because all the included studies were followed up to 1 to 3 years of age, the long-term effects of probiotics on atopy and food hypersensitivity cannot be defined in our study. Hence, follow-up of existing trials are warranted.

CONCLUSIONS

The current systematic review and meta-analysis suggested that probiotics administered prenatally and postnatally could reduce the risk of atopy and food hypersensitivity in young children. Future studies should consider the optimal probiotic strains, dosing, duration of therapy, and longer follow-up times. Researches assessing the effects of probiotics on confirmed food allergy rather than surrogate measure of food sensitization are warranted.

ACKNOWLEDGMENTS

We thank Jin-Liang Chen for his technical assistance and full-text articles acquisition.

REFERENCES

1. Odhiambo JA, Williams HC, Clayton TO, et al. Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three. J Allergy Clin Immunol. 2009;124:1251–1258.
2. Asher MI, Montefort S, Bjorksten B, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet. 2006;368:733–743.
3. Warner JO, Kaliner MA, Crisci CD, et al. Allergy practice worldwide: a report by the World Allergy Organization Specialty and Training Council. Int Arch Allergy Immunol. 2006;139:166–174.
4. Strachan DP. Hay fever, hygiene, and household size. Br Med J. 1989;299:1259–1260.
5. Okada H, Kuhn C, Feillet H, et al. The ‘hygiene hypothesis’ for autoimmune and allergic diseases: an update. Clin Exp Immunol. 2010;160:1–9.
6. Wold AE. The hygiene hypothesis revised: is the rising frequency of allergy due to changes in the intestinal flora? Allergy. 1998;53:20–25.
7. Joint FAO-WHO Working Group on Drafting Guidelines for the Evaluation of Probiotics in Food. Guidelines for the Evaluation of Probiotics in Food. London, Canada: Joint FAO/WHO Working Group Report; 2002 Available at: ftp://ftp.fao.org/es/esn/food/wgreport2.pdf.
8. Bjorksten B, Sepp E, Julge K, et al. Allergy development and the intestinal microflora during the first year of life. J Allergy Clin Immunol. 2001;108:516–520.
9. Sudo N, Sawamura S, Tanaka K, et al. The requirement of intestinal bacterial flora for the development of an IgE production system fully susceptible to oral tolerance induction. *J Immunol.* 1997;159:1739–1745.

10. Abrahamsson TR, Jakobsson HE, Andersson AF, et al. Low diversity of the gut microbiota in infants with atopic eczema. *J Allergy Clin Immunol.* 2012;129:434–440.

11. Wang M, Karlsson C, Olsson C, et al. Reduced diversity in the early fecal microbiota of infants with atopic eczema. *J Allergy Clin Immunol.* 2008;121:129–134.

12. Frei R, Akdis M, O’Mahony L. Prebiotics, probiotics, synbiotics, and the immune system: experimental data and clinical evidence. *Curr Opin Gastroenterol.* 2015;31:153–158.

13. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *Ann Intern Med.* 2009;151:W65–W94.

14. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions, version 5.1.0 (updated March 2011). The Cochrane Collaboration; 2011. Available at: www.cochrane-handbook.org.

15. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. *Br Med J.* 2011;343:d5926.

16. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. *Br Med J.* 2003;327:557–560.

17. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. *Br Med J.* 1997;315:629–634.

18. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. *Biometrics.* 1994;50:1088–1101.

19. Kalliomaki M, Salminen S, Poussa T, et al. Prebiotics during the first 7 years of life: a cumulative risk reduction of eczema in a randomized, placebo-controlled trial. *J Allergy Clin Immunol.* 2007;119:1019–1021.

20. Kalliomaki M, Salminen S, Poussa T, et al. Prebiotics and prevention of atopic disease: 4-year follow-up of a randomized placebo-controlled trial. *Lancet.* 2003;361:1869–1871.

21. Prescott SL, Witschut J, Taylor A, et al. Early markers of allergic disease in a primary prevention study using probiotics: 2.5-year follow-up phase. *Allergy.* 2008;63:1481–1490.

22. Wickens K, Black P, Stanley TV, et al. A protective effect of Lactobacillus rhamnosus HN001 against eczema in the first 2 years of life persists to age 4 years. *Clin Exp Allergy.* 2012;42:1071–1079.

23. Jensen MP, Meldrum S, Taylor AL, et al. Early probiotic supplementation for allergy prevention: long-term outcomes. *J Allergy Clin Immunol.* 2012;130:1209–1211.

24. West CE, Hamnarstrom ML, Hernell O. Probiotics in primary prevention of allergic disease: follow-up at 8-9 years of age. *Allergy.* 2013;68:1015–1020.

25. Abrahamsson TR, Jakobsson T, Bjorksten B, et al. No effect of prebiotics on respiratory allergies: a seven-year follow-up of a randomized controlled trial in infancy. *Pediatr Allergy Immunol.* 2013;24:556–561.

26. Loo EX, Llanora GV, Lu Q, et al. Supplementation with probiotics in the first 6 months of life did not protect against eczema and allergy in at-risk Asian infants: a 5-year follow-up. *Int Arch Allergy Immunol.* 2014;163:25–28.

27. Gorissen DM, Rutten NB, Oostermeijer CM, et al. Preventive effects of selected probiotic strains on the development of asthma and allergic rhinitis in childhood. the PANDA study. *Clin Exp Allergy.* 2014;44:1431–1433.

28. Allen SJ, Jordan S, Storey M, et al. Probiotics in the prevention of eczema: a randomised controlled trial. *Arch Dis Child.* 2014;99:1014–1019.

29. Wickens K, Black PN, Stanley TV, et al. A differential effect of 2 probiotics in the prevention of eczema and atopy: a double-blind, randomized, placebo-controlled trial. *J Allergy Clin Immunol.* 2008;122:788–794.

30. Kalliomaki M, Salminen S, Arvilommi H, et al. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. *Lancet.* 2001;357:1076–1079.

31. Rautava S, Kainenen E, Salminen S, et al. Maternal probiotic supplementation during pregnancy and breast-feeding reduces the risk of eczema in the infant. *J Allergy Clin Immunol.* 2012;130:1355–1360.

32. Huurre A, Laitinen K, Rautava S, et al. Impact of maternal atopy and probiotic supplementation during pregnancy on infant sensitization: a double-blind placebo-controlled study. *Clin Exp Allergy.* 2008;38:1342–1348.

33. Rautava S, Arvilommi H, Isolaire E. Specific probiotics in enhancing maturation of IgA responses in formula-fed infants. *Pediatr Res.* 2006;60:221–224.

34. Boyle RJ, Ismail IH, Kivivuo S, et al. Lactobacillus GG treatment during pregnancy for the prevention of eczema: a randomised controlled trial. *Allergy.* 2011;66:509–516.

35. Kim JY, Kwon JH, Ahn SH, et al. Effect of probiotic mix (Bifidobacterium bifidum, Bifidobacterium lactis, Lactobacillus acidophilus) in the primary prevention of eczema: a double-blind, randomized, placebo-controlled trial. *Pediatr Allergy Immunol.* 2010;21:e386–e393.

36. Kopp MV, Hennemuth I, Heinemann P, et al. Randomized, double-blind, placebo-controlled trial of probiotics for primary prevention: no clinical effects of *Lactobacillus GG* supplementation. *Pediatrics.* 2008;121:e850–e856.

37. Niers L, Martin R, Rijkers G, et al. The effects of selected probiotic strains on the development of eczema (the PANDA study). *Allergy.* 2009;64:1349–1358.

38. Soh SE, Aw M, Gerez I, et al. Probiotic supplementation in the first 6 months of life in at risk Asian infants: effects on eczema and atopic sensitization at the age of 1 year. *Clin Exp Allergy.* 2009;39:571–578.

39. Abrahamsson TR, Jakobsson T, Botthcher MF, et al. Probiotics in prevention of IgE-associated eczema: a double-blind, randomized, placebo-controlled trial. *J Allergy Clin Immunol.* 2007;119:1174–1180.

40. Taylor AL, Dunstan JA, Prescott SL. Probiotic supplementation for the first 6 months of life fails to reduce the risk of atopic dermatitis and increases the risk of allergen sensitization in high-risk children: a randomized controlled trial. *J Allergy Clin Immunol.* 2007;119:184–191.

41. Ou CY, Kuo HC, Wang L, et al. Prenatal and postnatal probiotics reduces maternal but not childhood allergic diseases: a randomized, double-blind, placebo-controlled trial. *Clin Exp Allergy.* 2012;42:1386–1396.

42. Dotterud CK, Storro O, Johnsen R, et al. Probiotics in pregnant women to prevent allergic disease: a randomized, double-blind trial. *Br J Dermatol.* 2010;163:616–623.

43. West CE, Hamnarstrom ML, Hernell O. Probiotics during weaning reduces the incidence of eczema. *Pediatr Allergy Immunol.* 2009;20:430–437.

44. Wu FL, Feng XB, Liu XX, et al. The influence of *Bifidobacteria* on the composition of breast milk and the relationship between *Bifidobacteria* and the incidence of allergic diseases in breast-fed infants. *J Clin Pediatr.* 2010;28:260–263. (In Chinese).

45. Kuitunen M. Probiotics and prebiotics in preventing food allergy and eczema. *Curr Opin Allergy Clin Immunol.* 2013;13:280–286.

46. West CE, Jenmalin MC, Prescott SL. The gut microbiota and its role in the development of allergic disease: a wider perspective. *Clin Exp Allergy.* 2015;45:43–53.
47. Marschan E, Kuitunen M, Kukkonen K, et al. Probiotics in infancy induce protective immune profiles that are characteristic for chronic low-grade inflammation. *Clin Exp Allergy.* 2008;38:611–618.

48. Jenmalm MC, Duchén K. Timing of allergy-preventive and immunomodulatory dietary interventions: are prenatal, perinatal or postnatal strategies optimal? *Clin Exp Allergy.* 2013;43:273–278.

49. Fiocchi A, Pawankar R, Cuello-Garcia C, et al. World Allergy Organization-McMaster University Guidelines for Allergic Disease Prevention (GLAD-P): probiotics. *World Allergy Organ J.* 2015;8:4.

50. Kuitunen M, Kukkonen K, Juntunen-Backman K, et al. Probiotics prevent IgE-associated allergy until age 5 years in cesarean-delivered children but not in the total cohort. *J Allergy Clin Immunol.* 2009;123:335–341.

51. Jakobsson HE, Abrahamsen TR, Jenmalm MC, et al. Decreased gut microbiota diversity, delayed Bacteroidetes colonization, and reduced Th1 responses in infants delivered by caesarean section. *Gut.* 2014;63:559–566.

52. Bäckhed F, Roswall J, Peng Y, et al. Dynamics and stabilization of the human gut microbiome during the first year of life. *Cell Host Microbe.* 2015;17:690–703.

53. Sanchez-Valverde F, Gil F, Martinez D, et al. The impact of caesarean delivery and type of feeding on cow’s milk allergy in infants and subsequent development of allergic march in childhood. *Allergy.* 2009;64:884–889.

54. Kolokotroni O, Middleton N, Gavatha M, et al. Asthma and atopy in children born by caesarean section: effect modification by family history of allergies: a population based cross-sectional study. *BMC Pediatr.* 2012;12:179.

55. Almqvist C, Craitttingius S, Lichtenstein P, et al. The impact of birth mode of delivery on childhood asthma and allergic diseases: a sibling study. *Clin Exp Allergy.* 2012;42:1369–1376.

56. Muraro A, Halken S, Arshad SH, et al. EAACI food allergy and anaphylaxis guidelines. Primary prevention of food allergy in children and adults: systemic reviews. *Allergy.* 2014;69:590–601.

57. Cosenza L, Nocerino R, Di Scala C, et al. Bugs for atopy: the *Lactobacillus rhamnosus* GG strategy for food allergy prevention and treatment in children. *Benef Microbes.* 2015;6:225–232.

58. Soares-Weiser K, Takwoingi Y, Panesar SS, et al. The diagnosis of food allergy: a systematic review and meta-analysis. *Allergy.* 2014;69:76–86.

59. Rautava S, Kalliomaki M, Isolauri E. Probiotics during pregnancy and breast-feeding might confer immunomodulatory protection against atopic disease in the infant. *J Allergy Clin Immunol.* 2002;109:119–121.

60. Sornasse T, Larenas PV, Davis KA, et al. Differentiation and stability of T helper 1 and 2 cells derived from naïve human neonatal CD4 + T cells, analyzed at the single-cell level. *J Exp Med.* 1996;184:473–483.

61. Shah A. The pathologic and clinical intersection of atopic and autoimmune disease. *Curr Allergy Asthma Rep.* 2012;12:520–529.

62. Yang J, Li W, Sun R, et al. The effect of *Lactobacillus johnsonii* Nce533 (Lal1) on the balance of Th1/Th2 cells in BALB/c mice. *Clin Invest Med.* 2011;34:E254.

63. Matsuzaki T, Takagi A, Ikemura H, et al. Intestinal microflora: probiotics and autoimmunity. *J Nutr.* 2007;137:798S–802S.

64. Elazab N, Mendy A, Gasana J, et al. Probiotic administration in early life, atopy, and asthma: a meta-analysis of clinical trials. *Pediatrics.* 2013;132:e666–e676.

65. Osborn DA, Sinn JK. Probiotics in infants for prevention of allergic disease and food hypersensitivity. *Cochrane Database Syst Rev.* 2007; CD006475.

66. Kong XY, Yang Y, Guan J, et al. Probiotics’ preventive effect on pediatric food allergy: a meta-analysis of randomized controlled trials. *Clin Med Sci J.* 2014;29:144–147.

67. Kuukkonen AK, Savilahti EM, Hahtela T, et al. Ovalbumin-specific immunoglobulins A and G levels at age 2 years are associated with the occurrence of atopic disorders. *Clin Exp Allergy.* 2011;41:1414–1421.

68. Berni Canani R, Nocerino R, Terrin G, et al. Effect of *Lactobacillus GG* on tolerance acquisition in infants with cow’s milk allergy: a randomized trial. *J Allergy Clin Immunol.* 2012;129:580–582.